• Amylyx announces end of enrollment for phase 3 trial of ALS therapeutic

    1 month ago - By Healio

    Amylyx Pharmaceuticals Inc. announced completion of enrollment for a global, phase 3 clinical trial of AMX0035, an oral, fixed-dose medication for ALS.
    According to a company release, the PHOENIX study is a 48-week, randomized, placebo-controlled trial conducted at more than 65 sites throughout Europe and the United States and will include 664 participants with ALS.
    The primary efficacy outcome of the study, Amylyx said in the release, will be joint assessment of ALS Functional Rating Scale-Revised total score progression over 48 weeks, adjusted for mortality. Participants have been randomized
    Read more ...

     

  • Vistagen completes acquisition of Pherin Pharmaceuticals

    Vistagen completes acquisition of Pherin Pharmaceuticals

    1 month ago - By Healio

    A California-based biopharmaceutical company has announced the completion of its acquisition of Pherin Pharmaceuticals Inc., a drug development firm that specializes in neuropsychiatric and neuroendocrine issues.
    According to a release from Vistagen, the sale allows it to own all intellectual property rights to Pherin's two most advanced drug candidates, PH94B - currently in phase 3 development for social anxiety disorder and phase 2 development for adjustment disorder with anxiety - and PH10, in clinical development for major depressive disorder.
    The acquisition also brings
    Read more ...